Attached files
| file | filename |
|---|---|
| EX-10.20 - EXHIBIT 10.20 - TG THERAPEUTICS, INC. | tgtx_ex1020.htm |
| EX-32.2 - EXHIBIT 32.2 - TG THERAPEUTICS, INC. | tgtx_ex322.htm |
| EX-32.1 - EXHIBIT 32.1 - TG THERAPEUTICS, INC. | tgtx_ex321.htm |
| EX-31.2 - EXHIBIT 31.2 - TG THERAPEUTICS, INC. | tgtx_ex312.htm |
| EX-23.1 - EXHIBIT 23.1 - TG THERAPEUTICS, INC. | tgtx_ex231.htm |
| EX-21.1 - EXHIBIT 21.1 - TG THERAPEUTICS, INC. | tgtx_ex211.htm |
| 10-K - 10-K - TG THERAPEUTICS, INC. | v031418_10K.htm |
Exhibit 31.1
CERTIFICATION OF PERIODIC
REPORT
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002
I,
Michael S. Weiss, certify that:
|
|
1.
|
I have reviewed this
annual report on Form 10-K of TG Therapeutics, Inc.;
|
|
|
2.
|
Based on my knowledge,
this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period
covered by this report;
|
|
|
3.
|
Based on my knowledge,
the financial statements, and other financial information included
in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this
report;
|
|
|
4.
|
The registrant’s other
certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and
have:
|
|
|
a)
|
Designed such disclosure
controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report
is being prepared;
|
|
|
b)
|
Designed such internal
control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting
principles;
|
|
|
c)
|
Evaluated the
effectiveness of the registrant’s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and
|
|
|
d)
|
Disclosed in this report
any change in the registrant’s internal control over
financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal
quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting;
and
|
|
|
5.
|
The registrant’s
other certifying officer(s) and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to
the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the
equivalent functions):
|
|
|
a)
|
All significant
deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to
record, process, summarize and report financial information;
and
|
|
|
b)
|
Any fraud, whether or
not material, that involves management or other employees who have
a significant role in the registrant’s internal control over
financial reporting.
|
|
Date: March 15,
2018
|
|
/s/ Michael S.
Weiss
|
|
|
Michael S.
Weiss
Executive Chairman, Chief Executive Officer and President Principal Executive Officer |
|